Adrenal Androgens - Chapter 3 : Adrenal Disease and Function - Bibliography

1. Longcope C. Adrenal and gonadal androgen secretion in normal females. In: Horton R, Lobo RA, eds. Clinics in Endocrinology and Metabolism. Philadelphia: W.B. Saunders, 1986:213-228.
2. Guyton Physiology 11th ed. Chapter 77. Adrenocortical Hormones.
3. Davis JO. Regulation of aldosterone secretion. In: Einstein AB e, ed. The adrenal cortex. Boston: Little, Brown, 1967:203-247.
4. Bech K, Tygstrup I, Nerup J. The involution of the foetal adrenal cortex. A light microscopic study. Acta Pathol.Microbiol.Scand. 1969;76:391-400.
5. Dhom G. The prepubertal and pubertal growth of the adrenal (adrenarche). Beir Pathol 1973;150:357-377.
6. Auchus RJ, Rainey WE. Adrenarche - physiology, biochemistry and human disease. Clin Endocrinol (Oxf). 2004 Mar;60(3):288-96. Review.
7. Auchus RJ. The physiology and biochemistry of adrenarche. Endocr Dev. 2011;20:20-7.
8. Parker CRJ, Mixon RL, Brissie RM, Grizzle WE. Aging alters zonation in the adrenal cortex of men. J.Clin.Endocrinol.Metab. 1997;82:3898-3901.
9. Kronenberg. Williams Textbook of Endocrinology 11th ed. Chapter 14. The adrenal cortex.
10. Hoekstra M., Van Berkel Theo JC., Van Eck M. A multi-purpose player in cholesterol and steroid metabolism. World J Gastroenterol. 2010 December 21;16(47):5916-5924
11. Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin North Am. 2005 Jun;34(2):293-313, viii. Review.
12. Jin Y, Penning TM. Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metab. 2001 Mar;15(1):79-94. Review.
13. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004 Dec;25(6):947-70.
14. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J.Clin.Endocrinol.Metab. 1997;82:2396-2402.
15. Brown JD, Doe RP. Pituitary pigmentary hormones. Relationship of melanocyte-stimulating hormone to lipotropic hormone. JAMA 1978;240:1273-1278.
16. Krieger DT, Liotta AS, Suda T, Goodgold A, Condon E. Human plasma immunoreactive lipotropin and adrenocorticotropin in normal subjects and in patients with pituitary-adrenal disease. J.Clin.Endocrinol.Metab. 1979;48:566-571.
17. Nicholson WE, Liddle RA, Puett D, Liddle GW. Adrenocorticotropic hormone biotransformation, clearance, and catabolism. Endocrinology 1978;103:1344-1351.
18. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394-1397.
19. Lamberts SW, Verleun T, Oosterom R, de Jong F, Hackeng WH. Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. J.Clin.Endocrinol.Metab. 1984;58:298-303.
20. Gardner D.G., Shoback D. Greenspan’s Basic & Clinical Endocrinology. 8th edition.Lange.Mc Graw Hill.
21. Ghizzoni L, Bernasconi S, Virdis R, Vottero A, Ziveri M, Volta C, Iughetti L, Giovannelli G. Dynamics of 24-hour pulsatile cortisol, 17-hydroxyprogesterone, and androstenedione release in prepubertal patients with nonclassic 21- hydroxylase deficiency and normal prepubertal children. Metabolism 1994;43:372-377.
22. Ghizzoni L, Mastorakos G, Vottero A, Magiakou MA, Chrousos GP, Bernasconi S. Spontaneous cortisol and growth hormone secretion interactions in patients with nonclassic 21-hydroxylase deficiency (NCCAH) and control children. J.Clin.Endocrinol.Metab. 1996;81:482-487.
23. Rosenfeld RS, Rosenberg BJ, Fukushima DK, Hellman L. 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. J.Clin.Endocrinol.Metab. 1975;40:850-855.
24. Feuillan P, Pang S, Schurmeyer T, Avgerinos PC, Chrousos GP. The hypothalamic-pituitary-adrenal axis in partial (late-onset) 21-hydroxylase deficiency. J.Clin.Endocrinol.Metab. 1988;67:154-160.
25. Parker LN. Control of adrenal androgen secretion. Endocrinol Metab Clin.North Am. 1991;20:401-421.
26. Thomas G, Frenoy N, Legrain S, Sebag-Lanoe R, Baulieu EE, Debuire B. Serum dehydroepiandrosterone sulfate levels as an individual marker. J.Clin.Endocrinol.Metab. 1994;79:1273-1276.
27. Warne GL, Carter JN, Faiman C, Reyes FI, Winter JS. Hormonal changes in girls with precocious adrenarche: a possible role for estradiol or prolactin. J.Pediatr. 1978;92:743-747.
28. Wathen NC, Perry L, Hodgkinson S, Chard T. The relationship between prolactin, dehydroepiandrosterone sulphate and testosterone in normally menstruating females. Acta Endocrinol.(Copenh.) 1985;109:173-175.
29. Sklar CA, Kaplan SL, Grumbach MM. Lack of effect of oestrogens on adrenal androgen secretion in children and adolescents with a comment on oestrogens and pubic hair growth. Clin.Endocrinol.(Oxf.) 1981;14:311-320.
30. Zachmann M, Manella B, Eiholzer U, Bucher H, Prader A. Influence of oestrogen in high and low doses on plasma steroid concentrations in girls with tall stature and Turner syndrome. Acta Endocrinol.(Copenh.) 1984;106:368-373.
31. Sobrinho LG, Kase NG, Grunt JA. Changes in adrenocortisol function of patients with gonadal dysgenesis after treatment with estrogen. J.Clin.Endocrinol.Metab. 1971;33:110-114.
32. Mattila AL, Perheentupa J, Pesonen K, Viinikka L. Epidermal growth factor in human urine from birth to puberty. J.Clin.Endocrinol.Metab. 1985;61:997-1000.
33. Keymolen V, Dor P, Borkowski A. Output of oestrogens, testosterone and their precursors by isolated human adrenal cells as compared with that of glucocorticosteroids. J.Endocrinol. 1976;71:219-229.
34. Parker LN, Lifrak ET, Kawahara CK, Geduld SI, Kozbur XM. Angiotensin II potentiates ACTH-stimulated adrenal androgen secretion. J.Steroid Biochem. 1983;18:205-208.
35. Zadik Z, Chalew SA, McCarter RJJ, Meistas M, Kowarski AA. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. J.Clin.Endocrinol.Metab. 1985;60:513-516.
36. Lee PA, Kowarski A, Migeon CJ, Blizzard RM. Lack of correlation between gonadotropin and adrenal androgen levels in agonadal children. J.Clin.Endocrinol.Metab. 1975;40:664-669.
37. Sizonenko PC, Paunier L. Hormonal changes in puberty III: Correlation of plasma dehydroepiandrosterone, testosterone, FSH, and LH with stages of puberty and bone age in normal boys and girls and in patients with Addison's disease or hypogonadism or with premature or late adrenarche. J.Clin.Endocrinol.Metab. 1975;41:894-904.
38. Glasow A, Breidert M, Haidan A, Anderegg U, Kelly PA, Bornstein SR. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J.Clin.Endocrinol.Metab. 1996;81:3103-3111.
39. Lobo RA, Kletzky OA, Kaptein EM, Goebelsmann U. Prolactin modulation of dehydroepiandrosterone sulfate secretion. Am.J.Obstet.Gynecol. 1980;138:632-636.
40. Yamaji T, Ishibashi M, Takaku F, Teramoto A, Takakura K, Takami M, Fukushima T, Kamoi K. Role of prolactin in age-related change in serum dehydroepiandrosterone sulphate concentrations. Acta Endocrinol.(Copenh.) 1989;120:655-660.
41. Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV.
Novel presence of luteinizing hormone/chorionic gonadotropin receptors in human adrenal glands. J Clin Endocrinol Metab. 1996 Jun;81(6):2397-400.
42. Rao C.V. Human adrenal LH/hCG receptors and what they could mean for adrenal physiology and pathology. Molecular and Cellular Endocrinology 329 (2010)33-36.Review.
43. Harold E. Carlson . Human adrenal cortex hyperfunction due to LH/hCG. Molecular and Cellular Endocrinology 269 (2007) 46–50. Review.

44. Ch.V. Rao, X.L. Zhou and Z.M. Lei. Functional Luteinizing Hormone/Chorionic Gonadotropin Receptors in Human Adrenal Cortical H295R Cells. Biology of Reproduction 71, 579–587 (2004).

45. Bornstein S.R.,Rutkowski H.,Vrezas I. Cytokines and steroidogenesis. Molecular and Cellular Endocrinology 215(2004)135-141.
46. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J.Clin.Endocrinol.Metab. 1993;77:1690-1694.
47. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J.Clin.Endocrinol.Metab. 1994;79:934-939.
48. Path G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J.Clin.Endocrinol.Metab. 1997;82:2343-2349.
49. Tkachenko IV, Jääskeläinen T, Jääskeläinen J, Palvimo JJ, Voutilainen R. Interleukins 1α and 1β as regulators of steroidogenesis in human NCI-H295R adrenocortical cells. Steroids. 2011 Sep-Oct;76(10-11):1103-15.
50. Smith R, Mesiano S, Chan EC, Brown S, Jaffe RB. Corticotropin-releasing hormone directly and preferentially stimulates dehydroepiandrosterone sulfate secretion by human fetal adrenal cortical cells. J.Clin.Endocrinol.Metab. 1998;83:2916-2920.
51. Smail PJ, Faiman C, Hobson WC, Fuller GB, Winter JS. Further studies on adrenarche in nonhuman primates. Endocrinology 1982;111:844-848.
52. Havelock JC, Auchus RJ, Rainey WE. The rise in adrenal androgen biosynthesis: adrenarche. Semin Reprod Med. 2004 Nov;22(4):337-47. Review.
53. Ghizzoni L, Virdis R, Ziveri M, Lamborghini A, Alberini A, Volta C, Bernasconi S. Adrenal steroid, cortisol, adrenocorticotropin, and beta-endorphin responses to human corticotropin-releasing hormone stimulation test in normal children and children with premature pubarche. J.Clin.Endocrinol.Metab. 1989;69:875-880.
54. Gell JS, Carr BR, Sasano H, Atkins B, Margraf L, Mason JI, Rainey WE. Adrenarche results from development of a 3beta-hydroxysteroid dehydrogenase-deficient adrenal reticularis. J.Clin.Endocrinol.Metab. 1998;83:3695-3701.
55. Mesiano S, Katz SL, Lee JY, Jaffe RB. Insulin-like growth factors augment steroid production and expression of steroidogenic enzymes in human fetal adrenal cortical cells: implications for adrenal androgen regulation. J.Clin.Endocrinol.Metab. 1997;82:1390-1396.
56. Fottner C, Engelhardt D, Weber MM. Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins. J.Endocrinol. 1998;158:409-417.
57. Fearon U, Clarke D, McKenna TJ, Cunningham SK. Intra-adrenal factors are not involved in the differential control of cortisol and adrenal androgens in human adrenals. Eur.J.Endocrinol. 1998;138:567-573.
58. Miller WL, Auchus RJ, Geller DH. The regulation of 17,20 lyase activity. Steroids 1997;62:133-142.
59. Zhang LH, Rodriguez H, Ohno S, Miller WL. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc.Natl.Acad.Sci.U.S.A. 1995;92:10619-10623.
60. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J.Clin.Invest. 1995;96:801-810.
61. Qin KN, Rosenfield RL. Role of cytochrome P450c17 in polycystic ovary syndrome. Mol.Cell Endocrinol. 1998;145:111-121.
62. Li M, Youngren JF, Dunaif A, Goldfine ID, Maddux BA, Zhang BB, Evans JL. Decreased Insulin Receptor (IR) Autophosphorylation in Fibroblasts from Patients with PCOS: Effects of Serine Kinase Inhibitors and IR Activators. J.Clin.Endocrinol.Metab.2002.Sep.;87.(9.):4088.-93. 87:4088-4093.
63. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr.Rev. 1997;18:774-800.
64. Takayama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J.Biol.Chem. 1988;263:3440-3447.
65. Chin JE, Dickens M, Tavare JM, Roth RA. Overexpression of protein kinase C isoenzymes alpha, beta I, gamma, and epsilon in cells overexpressing the insulin receptor. Effects on receptor phosphorylation and signaling. J.Biol.Chem. 1993;268:6338-6347.
66. Martens JW, Geller DH, Arlt W, Auchus RJ, Ossovskaya VS, Rodriguez H, Dunaif A, Miller WL. Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome. J.Clin.Endocrinol Metab 2000.Nov.;85.(11.):4338.-46. 85:4338-4346.
67. Auchus RJ. The regulation of human P450c17 activity:relashionship to premature adrenarche and the polycystic ovary syndrome. Trends Endocrinol Metab 1998;9:47-50. 63. Norman AW LG. Androgens. In: Norman and Litusassk eds, ed. Hormones. San Diego: 1987:483-513.
68. Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. I. Testerone metabolism in isolated hairs. J.Clin.Endocrinol.Metab. 1974;38:811-819.
69. Norman AW LG. Androgens. In: Norman and Litusassk eds, ed. Hormones. San Diego: 1987:483-513.
70. Schweikert HU, Wilson JD. Regulation of human hair growth by steroid hormones. I. Testerone metabolism in isolated hairs. J.Clin.Endocrinol.Metab. 1974;38:811-819.
71. Schweikert HU, Milewich L, Wilson JD. Aromatization of androstenedione by isolated human hairs. J.Clin.Endocrinol.Metab. 1975;40:413-417.
72. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J.Clin.Endocrinol.Metab. 1985;61:564-570.
73. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J.Clin.Endocrinol.Metab. 1990;70:473-479.
74. McNatty KP, Makris A, Reinhold VN, De Grazia C, Osathanondh R, Ryan KJ. Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity. Steroids 1979;34:429-443.
75. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER: Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 1981, 53:412-417.

76. Simpson ER, Ackerman GE, Smith ME, Mendelson CR: Estrogen formation in stromal cells of adipose tissue of women: induction by glucocorticoids. Proc Natl Acad Sci USA 1981, 78:5690-5694.

77. Zhao Y, Nichols JE, Bulnn SE, Mendelson CR, Simpson ER: Aromatase P450 gene expression in human adipose tissue. J Biol Chem 1995, 270:16449-16457.

78. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994, 15:342-355
79. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-839.
80. Kremer EJ, Pritchard M, Lynch M, Yu S, Holman K, Baker E, Warren ST, Schlessinger D, Sutherland GR, Richards RI. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)n. Science 1991;252:1711-1714.
81. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65:905-914.
82. Fu YH, Pizzuti A, Fenwick RGJ, King J, Rajnarayan S, Dunne PW, Dubel J, Nasser GA, Ashizawa T, de Jong P. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255:1256-1258.
83. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER. Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. Biochem.Biophys.Res.Commun.1994;198:74-80.
84. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, Nanus DM, Catterall JF. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J.Clin.Endocrinol.Metab. 1996;81:4400-4405.
85. Coetzee GA, Ross RK. Re: Prostate cancer and the androgen receptor. J.Natl.Cancer Inst. 1994;86:872-873.
86. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995;55:1937-1940.
87. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-79.
88. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic.Acids.Res. 1994;22:3181-3186.
89. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am.J.Hum.Genet. 1992;51:1229-1239.
90. Vottero A, Stratakis CA, Ghizzoni L, Longui CA, Karl M, Chrousos GP. Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation. J.Clin.Endocrinol Metab 1999;84:1091-1095.
91. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr.Rev.2002.Apr.;23.(2.):175.-200. 23:175-200.
92. Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, Lange PH, Gleave ME. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J.Biol.Chem. 1997;272:17485-17494.
93. Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P, Sun Z. SMAD3 represses androgen receptor-mediated transcription. Cancer Res.2001.Mar.1.;61.(5.):2112.-8. 61:2112-2118.
94. Kang HY, Lin HK, Hu YC, Yeh S, Huang KE, Chang C. From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc.Natl.Acad.Sci.U.S.A.2001.Mar.13.;98.(6.):3018.-23. 98:3018-3023.
95. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A, Janne OA. Mutual transcriptional interference between RelA and androgen receptor. J.Biol.Chem. 1996;271:24151-24156.
96. Aarnisalo P, Palvimo JJ, Janne OA. CREB-binding protein in androgen receptor-mediated signaling. Proc.Natl.Acad.Sci.U.S.A. 1998;95:2122-2127.
97. Yuan X, Lu ML, Li T, Balk SP. SRY interacts with and negatively regulates androgen receptor transcriptional activity. J.Biol.Chem.2001.Dec.7.;276.(49.):46647.-54. 276:46647-46654.
98. Schneikert J, Peterziel H, Defossez PA, Klocker H, Launoit Y, Cato AC. Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J.Biol.Chem. 1996;271:23907-23913.
99. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol.Cell Endocrinol.2000.Sep.25.;167.(1.-2.):139.-50. 167:139-150.
100. Chen S, Wang J, Yu G, Liu W, Pearce D. Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity. J.Biol.Chem. 1997;272:14087-14092.
101. Lee YF, Shyr CR, Thin TH, Lin WJ, Chang C. Convergence of two repressors through heterodimer formation of androgen receptor and testicular orphan receptor-4: a unique signaling pathway in the steroid receptor superfamily. Proc.Natl.Acad.Sci.U.S.A. 1999;96:14724-14729.
102. Lemon B, Tjian R. Orchestrated response: a symphony of transcription factors for gene control. Genes Dev.2000.Oct.15.;14.(20.):2551.-69. 14:2551-2569. 94.
103. Dorgan JF.,Longcope C.,Stephenson HE.Jr.,Falk RT.,Miller R.,Franz C.,Kahle L.,Campbell WS.,Tangrea JA.,Schatzkin A.Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996,5(7):533-539
104. Hankinson SE.,Willett WC.,Manson JE.,Colditz GA.,Hunter DJ.,Spiegelman D.,Barbieri RL.,Speizer FE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998, 90(17):1292-1299
105. Gonzalez L.O. ,Corte M.D. ,Vasquez J. ,Junquera S. ,Sanchez R. ,Alvarez A.C., Rodriguez J.C. Lamelas M.L.,Vizoso F.J. Androgen receptor expression in breast cancer:Relationship with clinicopathological characteristics of the tumors,prognosis and expression of metalloproteases and their inhibitors. BMC Cancer 2008,8:149
106. Collins L.C.,Cole K.S.,Marroti J.D.,Hu R.,Schnitt S.J.,Tamimi R.M. Androgen receptor expression in breast cancer in relation to molecular phenotype:results from the Nurses’Health Study. Modern Pathology 24,924-931,July 2011
107. Lillie EO.,Bernstein L.,Ursin G. The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 2003 5(3):164-173.
108. Wu MH.,Ma WL.,Hsu CL.,Chen YL.,Ou JH.,Ryan CK.,Hung YC.,Yeh S.,Chang C. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med. 2010 May 19;2(32):32ra35.
109. Yeh SH, Chang CF, Shau WY, Chen YW, Hsu HC, Lee PH, Chen DS, Chen PJ. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis.Cancer Res. 2002 Aug 1;62(15):4346-51.
110. Yu MW, Cheng SW, Lin MW, Yang SY, Liaw YF, Chang HC, Hsiao TJ, Lin SM, Lee SD, Chen PJ, Liu CJ, Chen CJ. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2000 Dec 20;92(24):2023-8.
111. Zheng Y, Chen Kl, Ma WL, Chang C, Ou JH "Enhancement of gene transactivation activity of androgen receptor by hepatitis B virus X protein." Virology, (2007):5;363(2):454-61.
112. Ma WL, Hsu CL, Wu MH, Wu CT, Wu CC, Lai JJ, Jou YS, Chen CW, Yeh S and Chang C "Androgen Receptor Is a New Potential Therapeutic Target for the
Treatment of Hepatocellular Carcinoma", Gastroenterology, (2008):135(3):947-55.
113. Chang C, Kokontis J, and Liao S "Molecular cloning of human and rat complementary DNA encoding androgen receptors." Science, (1988):240(4850), 324-326.
114.Chang C, and Liao S "Gene expression and structure analysis of cDNA's for androgen-sensitive proteins and different forms of steroid-receptors." Progress in Cancer Research and Therapy. (1988):35, 43-48.
115.S. Yeh, H. K. Lin, H. Y. Kang, T. H. Thin, M. F. Lin, C. Chang, From Her2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 96, 5458–5463 (1999).

116. Kumar R, Atamna H, Zakharov MN, Bhasin S, Khan SH, Jasuja R. Role of the androgen receptor CAG repeat polymorphism in prostate cancer, and spinal and bulbar muscular atrophy. Life Sci. 2011 Mar 28;88(13-14):565-71.

117. Y. Niu, S. Altuwaijri, S. Yeh, K. P. Lai, S. Yu, K. H. Chuang, S. P. Huang, H. Lardy, C. Chang, Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc. Natl. Acad. Sci. U.S.A. 105, 12188–12193 (2008).

118. Y. Niu, S. Altuwaijri, K. P. Lai, C. T. Wu, W. A. Ricke, E. M. Messing, J. Yao, S. Yeh, C. Chang, Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc. Natl.Acad. Sci. U.S.A. 105, 12182–12187 (2008).
119. Wang Y.,Li JQ.,Shao C.,Liu F.,Yang ZY.,Qiu JX.,Li YM.,Fu Q.,Zhang W.,Xue W.,Lei YH.,Gao JY.,Wang JY.,Gao XP.,Yuan JL.,Bao TY.,Zhang YT. Androgen receptor coregulators NOCR1,TIF2 and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cell. Ir J Med Sci.2011 Jul 5.
120. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Hu YC, Tsai MY, Yeh S, Messing E and Chang C "Promotion of Bladder Cancer Development and Progression by Androgen Receptor Signals" JNCI, (2007):99: 558 - 68.
121. Chang C. et al. Bladder Cancer Linked To Androgens And Androgen Receptor In Mice. Journal of the National Cancer Institute .2007, April 5.
122. Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol Cell Endocrinol. 2011 Jun 16.
123. Zhang X, Lanter JC, Sui Z. Recent advances in the development of selective androgen receptor modulators. Expert Opin Ther Pat. 2009 Sep;19(9):1239-58. Review.
124. Casson PR, et al. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod, 2000;15:2129-2132.
125. Barad and Gleicher.Effect of dehydroepiandrostenone on oocyte and embryo yields, embryo grade and cell numbers in IVF. Human Reproduction 2006 Nov.Vol. 21, Issue 11, Pp. 2845-2849.
126. Gleicher N., Ryan, E., Weghofer, A., Blanco-Mejia, S., and Barad, D.H. (2009). "Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study". Reproductive Biology and Endocrinology 2009, 7:108
127. Barnhart KT, Freeman E, Grisso JA, Rader DJ, Sammel M, Kapoor S, Nestler JE. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab. 1999 Nov;84(11):3896-902.
128. Genazzani AR, Pluchino N. DHEA therapy in postmenopausal women: the need to move forward beyond the lack of evidence. Climacteric. 2010 Aug;13(4):314-6. Review.
129. Davis SR, Panjari M, Stanczyk FZ. Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab. 2011 Jun;96(6):1642-53.
130. Genazzani AD, Lanzoni C, Genazzani AR. Might DHEA be considered a beneficial replacement therapy in the elderly? Drugs Aging. 2007;24(3):173-85. Review.
131. Fernand Labrie. DHEA, important source of sex steroids in men and even more in women. L. Martini (Eds.) Progress in Brain Research, Vol. 182 (2010).
132. Mary Panjari, Susan R. Davis. Vaginal DHEA to treat menopause related atrophy: A review of the evidence . Maturitas 2010 Clinical review: DHEA replacement for postmenopausal women.
133. Saltzman E, Guay A. Dehydroepiandrosterone therapy as female androgen replacement. Semin Reprod Med. 2006 Apr;24(2):97-105. Review.
134. Buvat J. Androgen therapy with dehydroepiandrosterone. World J Urol. 2003 Nov;21(5):346-55.
135. Allolio B, Arlt W, Hahner S. DHEA: why, when, and how much--DHEA replacement in adrenal insufficiency. Ann Endocrinol (Paris). 2007 Sep;68(4):268-73.
136. Neary N, Nieman L. Adrenal insufficiency: etiology, diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):217-23. Review.
137. Arlt, W., Callies, F., Van Vlijmen, J.C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D., Oettel, M., Ernst, M., Schulte, H.M. & Allolio, B. (1999) Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine, 341, 1013–1020.

138. Arlt, W., Callies, F., Koehler, I., Van Vlijmen, J.C., Fassnacht, M., Strasburger, C.J., Seibel, M.J., Huebler, D., Ernst, M., Oettel, M., Reincke, M., Schulte, H.M. & Allolio, B. (2001) Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. Journal of Clinical Endocrinology and Metabolism, 86, 4686–4692.
139. Martina, V.; Benso, A.; Gigliardi, V. R. et al. (2006). "Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects". Clin. Endocrinol. (Oxf.) 11 (March;64(3)): 260–4.
140. Zang H, Davis SR. Androgen replacement therapy in androgen-deficient women with hypopituitarism. Drugs. 2008;68(15):2085-93. Review.
141. Rice SP, Agarwal N, Bolusani H, Newcombe R, Scanlon MF, Ludgate M, Rees DA. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab. 2009 Jun;94(6):1966-72.
142. Chen CC, Parker CR Jr. Adrenal androgens and the immune system. Semin Reprod Med. 2004 Nov;22(4):369-77.
143. Hechter, A. Grossman and R.T. Chatterton Jr (1887). "Relationship of dehydroepiandrosterone and cortisol in disease". Medical Hypotheses 49 (1): 85–91.

144. Wolkowitz, O. M.; Reus, V. I.; Keebler, A. et al. (2006). "Double-blind treatment of major depression with dehydroepiandrosterone". Psychopharmacology (bo-controlled study) 188 (4): 541–551.
145.Young, E. A.; Haskett, R. F.; Grunhaus, L.; et al., A; Weinberg, VM; Watson, SJ; Akil, H (1994). "Increased evening activation of the hypothalamic–pituitary–adrenal axis in depressed patients". Archives of General Psychiatry 51 (9): 701–707.
146.Peter Gallagher BSc(Hons) and Allan Young MB, ChB, MPhil, Ph.D, MRCPsych (2002). "Cortisol/DHEA Ratios in Depression". Neuropsychopharmacology 26.
147. Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab. 2011 Mar;96(3):623-31.
148. Kasperk CH, Wakley GK, Hierl T, Ziegler R. Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J.Bone Miner.Res. 1997;12:464-471.
149. Hofbauer LC, Hicok KC, Khosla S. Effects of gonadal and adrenal androgens in a novel androgen-responsive human osteoblastic cell line. J.Cell Biochem. 1998;71:96-108.